Raymond Schinazi讨论早期抗逆转录病毒药物和索非布韦的发现

Q1 Medicine Pathogens and Immunity Pub Date : 2023-11-06 DOI:10.20411/pai.v8i2.624
Michael M. Lederman, Neil Greenspan
{"title":"Raymond Schinazi讨论早期抗逆转录病毒药物和索非布韦的发现","authors":"Michael M. Lederman, Neil Greenspan","doi":"10.20411/pai.v8i2.624","DOIUrl":null,"url":null,"abstract":"In this interview, Raymond Schinazi, PhD, Hon DSc, talks about his career with Michael M. Lederman, MD, and Neil S. Greenspan, MD, PhD, senior editors of Pathogens and Immunity. Dr. Schinazi has invented numerous powerful antiviral agents including the antiretrovirals lamivudine (3TC) and emtricitabine (FTC) and was instrumental in the discovery of the anti-hepatitis C agent sofosbuvir. These drugs have saved millions of lives and, here, Dr. Schinazi shares in detail how these agents were invented, how they work, and how they are being applied. He also offers his thoughts about newer approaches to treat viral infections.","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"14 6","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Raymond Schinazi Discusses the Discovery of Early Antiretroviral Agents and Sofosbuvir\",\"authors\":\"Michael M. Lederman, Neil Greenspan\",\"doi\":\"10.20411/pai.v8i2.624\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this interview, Raymond Schinazi, PhD, Hon DSc, talks about his career with Michael M. Lederman, MD, and Neil S. Greenspan, MD, PhD, senior editors of Pathogens and Immunity. Dr. Schinazi has invented numerous powerful antiviral agents including the antiretrovirals lamivudine (3TC) and emtricitabine (FTC) and was instrumental in the discovery of the anti-hepatitis C agent sofosbuvir. These drugs have saved millions of lives and, here, Dr. Schinazi shares in detail how these agents were invented, how they work, and how they are being applied. He also offers his thoughts about newer approaches to treat viral infections.\",\"PeriodicalId\":36419,\"journal\":{\"name\":\"Pathogens and Immunity\",\"volume\":\"14 6\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathogens and Immunity\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20411/pai.v8i2.624\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20411/pai.v8i2.624","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

在这次采访中,Raymond Schinazi博士,Hon DSc,谈到了他与Michael M. Lederman医学博士和Neil S. Greenspan医学博士,病原体和免疫资深编辑的职业生涯。他发明了许多强大的抗病毒药物,包括抗逆转录病毒药物拉米夫定(3TC)和恩曲他滨(FTC),并在发现抗丙型肝炎药物sofosbuvir方面发挥了重要作用。这些药物挽救了数百万人的生命,在这里,Schinazi博士详细分享了这些药物是如何发明的,它们是如何工作的,以及它们是如何应用的。他还提出了他对治疗病毒感染的新方法的看法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Raymond Schinazi Discusses the Discovery of Early Antiretroviral Agents and Sofosbuvir
In this interview, Raymond Schinazi, PhD, Hon DSc, talks about his career with Michael M. Lederman, MD, and Neil S. Greenspan, MD, PhD, senior editors of Pathogens and Immunity. Dr. Schinazi has invented numerous powerful antiviral agents including the antiretrovirals lamivudine (3TC) and emtricitabine (FTC) and was instrumental in the discovery of the anti-hepatitis C agent sofosbuvir. These drugs have saved millions of lives and, here, Dr. Schinazi shares in detail how these agents were invented, how they work, and how they are being applied. He also offers his thoughts about newer approaches to treat viral infections.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pathogens and Immunity
Pathogens and Immunity Medicine-Infectious Diseases
CiteScore
10.60
自引率
0.00%
发文量
16
审稿时长
10 weeks
期刊最新文献
Historical Highlight: The Luria-Delbrück Fluctuation Test - A Study of the Nature of Bacterial Mutations Conferring Resistance to Infection by Bacteriophage. Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies. Jonathan Yewdell Discusses Viral Immunology, Vaccine Development, Navigating a Scientific Career, and Offers Perspectives on Transforming Scientific Publishing and Research Education. Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice. People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1